Clinical trials: Anti-Retroviral Agents
HIV Infections
Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy
The purpose of this study is to compare GW433908 and nelfinavir when each is given with abacavir and lamivudine to HIV patients who have not taken antiretroviral drugs.
- Trial name
- NCT00008554
- Testing
- Abacavir sulfate, Nelfinavir mesylate, Lamivudine
- Where
- 23 sites in United States
- Volunteers
- 210 people
- Sponsor
- Glaxo Wellcome
HIV
Structured Treatment Interruption for HIV Patients With Virologic Failure
The purpose of this study is to assess the virologic impact of switching treatment-experienced HIV-infected patients with virologic failure to a salvage regimen with or without a 12 week STI prior to the switch.
- Trial name
- NCT00188851
- Testing
- therapeutic management strategy
- Volunteers
- 196 people
- Sponsor
- University Health Network, Toronto
HIV, HIV Antiretroviral Therapy (ART) Adherence
Pilot Study to Evaluate the Decentralization of Patient Care Among People With HIV in Out-of-hospital Settings
The goal of this 24-week, open-label, randomized pilot study is to assess the feasibility and impact of decentralized HIV care in a community setting (BCN Checkpoint), focusing on patient satisfaction and experience and carbon…
- Conditions
- HIV, HIV Antiretroviral Therapy (ART) Adherence, Health Care Delivery
- Trial name
- OOH (NCT07792070)
- Testing
- Implemention of the decentralization of patient care into communitary facilities such as BCN Checkpoint/BCN Prep·Point.
- Where
- Spain
- Volunteers
- 54 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
HIV Infections
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in…
- Trial name
- NCT07682961
- Testing
- Lenacapavir, Lenacapavir Tablet, Teropavimab
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 590 people
- Sponsor
- Gilead Sciences
HIV-1-infection
Measurement for Viral Reservoir and Immune Function in HIV-1-infected Patients Under Antiretroviral Therapy
Current antiretroviral therapy (ART) is highly effective to suppress plasma viral load to below the detection limit and to restore the host immunity, thus to prolong the survival of HIV-1-infected patients remarkably.
- Trial name
- NCT04068441
- Testing
- no intervention
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- National Taiwan University Hospital
Primary Biliary Cirrhosis
Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis
Patients with primary biliary cirrhosis (PBC) develop progressive liver disease and often require liver transplantation. The cause of disease is unknown.
- Trial name
- HAART (NCT01614405)
- Testing
- TDF/FTC/LPV/r
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- University of Alberta
Coronary Heart Disease, Heart Failure
Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 5 Years Follow-up
HIV-infection is associated not only with a reduced function of the immune system, but also linked with diseases of other organ systems, in particular with the heart.
- Conditions
- Coronary Heart Disease, Heart Failure, HIV, AIDS
- Trial name
- NCT01196273
- Testing
- Comprehensive non invasive cardiovascular examination
- Where
- 5 sites in Germany
- Volunteers
- 1,424 people
- Sponsor
- University Hospital, Essen
HIV Infections
Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)
The objective of this study is to demonstrate the safety and efficacy of tipranavir/ritonavir versus an active control arm in highly treatment experienced Human immunodeficiency virus-1 infected patients.
- Trial name
- NCT00144170
- Testing
- Tipranavir (with low dose ritonavir), Comparator protease inhibitor(CPI)/low dose ritonavir(r)
- Where
- 174 sites in Argentina, Austria and 15 more
- Volunteers
- 882 people
- Sponsor
- Boehringer Ingelheim
Coronary Heart Disease, Dyslipidemia
Cardiovascular Risk Factor Management in HIV Infection
There is growing evidence that antiretroviral therapy (ART) increases the risk of coronary heart disease (CHD) through metabolic side effects, such as dyslipidemia, insulin resistance, and type II diabetes.
- Conditions
- Coronary Heart Disease, Dyslipidemia, Diabetes Mellitus, Non-Insulin-Dependent, HIV Infection
- Trial name
- NCT00264394
- Testing
- Updated CHD risk profiles, Guidelines
- Where
- 7 sites in Switzerland
- Volunteers
- 4,097 people
- Sponsor
- University Hospital, Basel, Switzerland
HIV Infections, Anus Neoplasms
A Study of Anal Cancer Development in HIV Infected People
The purpose of this study is to compare the development of abnormal cell growth or cancer in the anal region of individuals who are receiving one of two different anti-HIV treatment strategies.
- Trial name
- NCT00107679
- Where
- 13 sites in United States
- Volunteers
- 560 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children
This study will evaluate a new treatment strategy called therapeutic drug monitoring (TDM) in HIV-infected children and adolescents.
- Trial name
- NCT00032669
- Testing
- HAART
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
HIV-1-infection
Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women
The goals of this clinical study are to learn more about the study drugs, VRC07-523LS, CAP256V2LS, and vesatolimod (VES) and how safe it is in women that have HIV and are on antiretroviral therapy (ART).
- Trial name
- NCT05281510
- Testing
- Vesatolimod, VRC07523LS, CAP256V2LS
- Where
- South Africa
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
HIV Infections
Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors
The purpose of this study is to see if it is safe and effective to give an anti-HIV drug combination containing indinavir and ritonavir to HIV-positive patients who have failed previous treatment with protease inhibitors.
- Trial name
- NCT00002361
- Testing
- Indinavir sulfate, Ritonavir
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART
The combination of two nucleoside analogues and one protease inhibitor is a highly active antiretroviral therapy (HAART) in HIV infected adults.
- Trial name
- NCT00196612
- Testing
- emtricitabine, FTC (drug), didanosine, ddI (drug), efavirenz (drug)
- Where
- France
- Volunteers
- 350 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment
Both ritonavir (RTV) and indinavir (IDV) are approved by the FDA to treat HIV, but IDV has not been approved for use in children and the doses for the combination of the two drugs has not been studied in children.
- Trial name
- NCT00012519
- Testing
- indinavir sulfate, ritonavir
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 29 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of Interleukin-7 in HIV Infected People Currently Taking Anti-HIV Drugs
The purpose of this study is to determine the safety of a single, under-the-skin dose of interleukin-7 (IL-7) in HIV infected people currently taking anti-HIV drugs.
- Trial name
- NCT00099671
- Testing
- Recombinant human interleukin-7
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Study to Assess the Safety and Durability of Viral Control Beyond 24 Weeks of Analytical Treatment Interruption After the Administration of Candidate HIV-1 Vaccines DNA.HTI, MVA.HTI and ChAdOx1.HTI or Placebo in Early Treated HIV-1 Positive Individuals (ATI Extension of AELIX-002 Study)
The AELIX-002 trial has been conducted on a cohort of individuals who started cART within the first 6 months after the primary VIH infection, thus increasing the likelihood of observing a certain rate of post-treatment controls…
- Trial name
- NCT04385875
- Testing
- Vaccine + extension of the ATI period
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
HIV Infections
Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
The goal of this trial is to demonstrate that new treatments are as effective as a reference triple-agent regimen in driving plasma viral load below the detection limit early during treatment (16 weeks).
- Trial name
- DAYANA (NCT00573001)
- Testing
- Tenofovir/Emtricitabine (Truvada) and Nevirapine, Tenofovir/Emtricitabine/Efavirenz (Atripla), Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)
- Where
- 2 sites in Cameroon, Senegal
- Volunteers
- 120 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Acquired Immunodeficiency Syndrome, HIV Infections
Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
The primary objectives of this study are to evaluate the steady-state pharmacokinetics (PK) and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) single-tablet regimen…
- Trial name
- NCT01721109
- Testing
- EVG/COBI/FTC/TDF
- Where
- 18 sites in United States, South Africa and 1 more
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
HIV
An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy
To test the hypothesis that AGT103-T cells therapy will allow HIV positive individual to reduce, modify or eliminate antiretroviral therapy.
- Trial name
- NCT05540964
- Testing
- Antiretroviral Therapy Interruption(ATI)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- American Gene Technologies International Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.